Companion diagnostics offers a set of tools that facilitates biological and clinical information to the pharmaceutical companies that they have to overcome. Companion diagnostics help physicians to improve the treatment decisions for the patients depending on their response to current treatments. Companion diagnostics approach to medication is transforming the healthcare industry by eliminating unfavorable reactions, improving treatment outcomes, and reducing the cost and time difficulties associated with conventional methods of medication. Companion diagnostic is basically a bio-analytical method designed to evaluate whether the patient will respond favorably to the specific medical treatment or not. The market is fully dependent on discovery of biomarkers, and research and development of new drugs. With the surge in research and development of targeted rehabilitations and innovation of new biomarkers for a range of conditions, the global companion diagnostics market is growing at healthy rate.
For more information visit: https://www.psmarketresearch.com/market-analysis/companion-diagnostics-market
Several targeted drugs in association with a companion diagnostics test are developed and have reached to large numbers of consumers. Large and small biopharmaceutical companies actively develop drug diagnostic combination products which are fast to surpass traditional drugs, favoring the concept of one-size-fits-all. U.S. Food and Drug Administration (FDA) have approved companion diagnostics for lung colorectal, breast, and melanoma. Some of the companion diagnostics devices are erbitux vectibix, lynparza, gilotrif, herceptin, exjade, gleevec, zelboraf and tarceva.
On the basis of technology, the companion diagnostics market can be bifurcated as immunohistochemistry test (IHC), polymerase chain reaction tests (PCR), and in situ hybridization tests (ISH). Based on the application, the global companion diagnostics market can be categorized as breast cancer, gastric cancer, colorectal cancer, melanoma, and lung cancer. Further on the bases of end users, the global companion diagnostics market can be categorized as reference laboratories and pharmaceutical companies.
Regulatory agencies, such as FDA, are encouraging the use of companion diagnostics in the development and use of prescribed drugs. The guidance started in 2004 in the form of FDA critical path initiative and was followed by the drug diagnostic co-development concept in 2005.
Request for Table of Content: https://www.psmarketresearch.com/market-analysis/Companion-Diagnostics-Market/toc-sample
Some of the major competitors in companion diagnostics market are Thermo Fisher Scientific, Inc., Ventana Medical Systems Inc, Biogenex Laboratories Inc, Agilent Technologies, Leica Microsystems GmbH, Abbott Laboratories, Inc., Danaher Corporation, Myriad Genetics, Life Technologies, Inc., BioMerieux SA, Roche Diagnostics, and GE Healthcare.
About P&S Market Research
P&S Market Research is a global market research and consulting company. We provide market research reports, industry reports; business intelligence and research based consulting services across a range of industries.
With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our publication. Our research assists our client in identifying new and different windows of opportunity and frame informed and customized strategies for expansion in different regions.
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY – 10016
US/ Canada Toll-Free: 1-888-778-7886